Quarterly report · Q2
4574.TEDINET S100OZLM
Period2022-01-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.9bn | 2022-01-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥11.3bn | 2021-01-01 → 2021-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.1bn | 2021-01-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | −¥2.4bn | 2022-01-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | −¥2.3bn | 2021-01-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | −¥2.5bn | 2022-01-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥6.1bn | 2021-01-01 → 2021-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.7bn | 2021-01-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥2.8bn | 2022-01-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥2.9bn | 2021-01-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥2.8bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥9.6bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.4bn | 2021-01-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥2.8bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | −¥2.4bn | 2021-01-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥17.4bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥22.5bn | at 2021-12-31 | Cons. | Assets |
| Total assets | ¥27.2bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.2bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥9.7bn | at 2021-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥10.2bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥12.8bn | at 2021-12-31 | Cons. | Net assets |
| Net assets / equity | ¥20.0bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.7bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.8bn | at 2021-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.4bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.5bn | at 2021-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.7bn | at 2021-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2020-12-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥631m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.6bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.3bn | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥96m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.6bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥501m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥4.0bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥3.3bn | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-64.17 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-24.05 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-220.52 | 2021-01-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-54.62 | 2021-01-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-51.11 | 2021-04-01 → 2021-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 58.4% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.8% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.5% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2022-01-01 → 2022-06-30 | ¥4m |
| Otherother segments | revenue external | 2022-01-01 → 2022-06-30 | ¥4m |
| Otherother segments | segment profit | 2022-01-01 → 2022-06-30 | −¥11m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-06-30 | −¥645m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥365m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥365m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥1.6bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥1.5bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥1.5bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥117m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-06-30 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-06-30 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-06-30 | −¥1.8bn |
| Otherother segments | revenue | 2021-01-01 → 2021-06-30 | ¥3m |
| Otherother segments | revenue external | 2021-01-01 → 2021-06-30 | ¥3m |
| Otherother segments | segment profit | 2021-01-01 → 2021-06-30 | −¥12m |
| Reconciling Itemsreconciling | segment profit | 2021-01-01 → 2021-06-30 | −¥723m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥3.1bn |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥3.1bn |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2021-01-01 → 2021-06-30 | −¥2.1bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥2.0bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥2.0bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2021-01-01 → 2021-06-30 | ¥594m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-01-01 → 2021-06-30 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-01-01 → 2021-06-30 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-01-01 → 2021-06-30 | −¥1.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 517
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 3255172 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.0746 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 3248638 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0744 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 2897100 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0664 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 2614315 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0599 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 2462700 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0564 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 2398800 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0550 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 1896000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0434 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 1308000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0300 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 1212300 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0278 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 1192500 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0273 | |
| Number of shares held | CurrentQuarterInstant | 22485525 | |
| Shareholding ratio | CurrentQuarterInstant | 0.5152 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 499800 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 43617500 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 436175 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 19600 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 44136900 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 436175 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 499800 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 499800 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0113 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 499800 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 499800 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0113 | |
| Number of male directors and other officers | FilingDateInstant | 5 | |
| Number of female directors and other officers | FilingDateInstant | － | |
| Ratio of female directors and other officers | FilingDateInstant | － | |
| Cash and deposits | Prior1YearInstant | 5796000000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 4705000000 | JPY |
| Notes and accounts receivable trade | Prior1YearInstant | 4056000000 | JPY |
| Notes and accounts receivable trade | CurrentQuarterInstant | 1132000000 | JPY |
| Short term investment securities | Prior1YearInstant | 302000000 | JPY |
| Short term investment securities | CurrentQuarterInstant | 702000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 2010000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |